CASBF OTC
CanSino Biologics Inc.
1W: +57.6%
1M: +1.1%
3M: +78.8%
YTD: -1.9%
1Y: -29.6%
3Y: +3.3%
5Y: -88.2%
$4.65
+1.70 (+57.73%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$1.0B
+26.1% ▲
5Y CAGR: +111.0%
Gross Profit
$0
-100.0% ▼
Operating Income
$23M
+105.8% ▲
Net Income
$27M
+107.2% ▲
EPS (Diluted)
$0.11
+107.2% ▲
EBITDA
$23M
+121.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $1.0B | $345M | $825M | $1.0B |
| YoY Growth | +17174.8% | -76.0% | -66.5% | +139.0% | +26.1% |
| Cost of Revenue | $1.3B | $1.2B | $1.2B | $244M | $0 |
| Gross Profit | $3.0B | -$187M | -$876M | $580M | $0 |
| Gross Margin | 69.8% | -18.1% | -253.8% | 70.4% | 0.0% |
| R&D Expenses | $879M | $778M | $638M | $416M | $0 |
| SG&A Expenses | $338M | $545M | $648M | $563M | $0 |
| Operating Expenses | $1.2B | $1.2B | $1.2B | $984M | $1.0B |
| Operating Income | $1.9B | -$1.4B | -$2.0B | -$403M | $23M |
| Operating Margin | 45.1% | -132.8% | -589.6% | -48.9% | 2.2% |
| Interest Expense | $20M | $41M | $64M | $60M | $0 |
| Income Before Tax | $1.9B | -$1.2B | -$2.0B | -$381M | $21M |
| Tax Expense | $30M | -$219M | -$11M | $2M | $0 |
| Net Income | $1.9B | -$909M | -$1.5B | -$379M | $27M |
| Net Margin | 44.5% | -88.2% | -429.6% | -45.9% | 2.6% |
| EPS (Diluted) | $7.74 | $-3.69 | $-6.01 | $-1.53 | $0.11 |
| EBITDA | $1.8B | -$1.3B | -$1.6B | -$110M | $23M |
| Shares Outstanding | 247M | 247M | 247M | 247M | 253M |